We aimed to assess the efficacy and safety of an all-oral , fixed-dose combination of the hepatitis C virus NS@A inhibitor ledipasvir and the NS@B nucleotide polymerase inhibitor sofosbuvir with and without ribavirin for @ weeks in treatment-naive and previously treated Japanese patients with chronic genotype @ hepatitis C virus infection .